+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator



Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator



Puerto Rico Health Sciences Journal 16(1): 9-14



A polyantigenic immunomodulator (PAI), previously known as polyantigenic vaccine, which consists of a mixture of antigens of inactivated bacteria with antigens of influenza virus in a peanut oil-arlacel-A-aluminium monoesterate emulsion, increased tumour resistance and induced tumour regression in tumour-bearing mice. This report presents clinical and laboratory data that demonstrate the effect of PAI in long-term prolongation of disease-free state in HIV-positive patients.

(PDF emailed within 1 workday: $29.90)

Accession: 002973040

Download citation: RISBibTeXText

PMID: 9160397


Related references

Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. American Journal of Clinical Oncology 30(6): 580-587, 2007

Expected life span survival rate and life quality in patients treated in the intensive care unit. Acta Anaesthesiologica Scandinavica Supplementum (SUPPL 72): 103, 1981

Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): I--Utilization of cimetidine and cyclosporine A. Boletin de la Asociacion Medica de Puerto Rico 81(7): 246-253, 1989

Cytokine immunomodulation and suppression of viral replication in HIV-infected cells by polyantigenic immunomodulator. FASEB Journal 14(6): A940, April 20, 2000

Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): II--Involvement of NK cells and adoptive immunotherapy. Boletin de la Asociacion Medica de Puerto Rico 81(7): 254-258, 1989

Health-related quality of life as a survival predictor for patients with oral cancer: is quality of life associated with long-term overall survival?. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 114(6): 756-763, 2013

Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer. Clinical Oncology ()) 20(3): 227-233, 2008

Quality of life in patients with end-stage renal disease treated with hemodialysis: survival is not enough!. Journal of Nephrology 21 Suppl 13: S54-S58, 2008

Changes in viral expression and cytokine profile induced by polyantigenic immunomodulator in HIV-infected peripheral blood mononuclear cells. Cellular & Molecular Biology (Noisy-Le-Grand) 41(SUPPL 1): S93-S101, 1995

Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 100(2): 425-432, 2004

Survival and quality of life in 23 patients with severe aplastic anemia treated with bone marrow transplantation (BMT). Blut 54(3): 137-146, 1987

Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases. Ortopedia, Traumatologia, Rehabilitacja 5(3): 276-283, 2007

Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest 127(4): 1212-1218, 2005

Survival and quality of life in oropharyngeal cancer patients treated with primary chemoradiation after salivary gland transfer. Journal of Laryngology and Otology 130(8): 755-762, 2016